Related Experiment Video
Updated: Feb 7, 2026

Fluorescence-Based Detection of FEN1 Nuclease Activity and Screening of Small-Molecule Inhibitors
Published on: June 27, 2025
Small molecule activator of Nm23/NDPK as an inhibitor of metastasis
Jae-Jin Lee1, Hwang Suk Kim2, Ji-Sun Lee3
1Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul, 03760, Korea.
Abstract:
Nm23-H1/NDPK-A is a tumor metastasis suppressor having NDP kinase (NDPK) activity. Nm23-H1 is positively associated with prolonged disease-free survival and good prognosis of cancer patients. Approaches to increasing the cellular levels of Nm23-H1 therefore have significance in the therapy of metastatic cancers. We found a small molecule, (±)-trans-3-(3,4-dimethoxyphenyl)-4-[(E)-3,4-dimethoxystyryl]cyclohex-1-ene, that activates Nm23, hereafter called NMac1. NMac1 directly binds to Nm23-H1 and increases its NDPK activity. Employing various NMac1 derivatives and hydrogen/deuterium mass spectrometry (HDX-MS), we identified the pharmacophore and mode of action of NMac1. We found that NMac1 binds to the C-terminal of Nm23-H1 and induces the NDPK activation through its allosteric conformational changes. NMac1-treated MDA-MB-231 breast cancer cells showed dramatic changes in morphology and actin-cytoskeletal organization following inhibition of Rac1 activation. NMac1 also suppressed invasion and migration in vitro, and metastasis in vivo, in a breast cancer mouse model. NMac1 as an activator of NDPK has potential as an anti-metastatic agent.
Insights
A novel small molecule, NMac1, activates Nm23-H1 (nucleoside diphosphate kinase A), a tumor metastasis suppressor. This activation inhibits cancer cell invasion and migration, showing potential as an anti-metastatic therapy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Nm23-H1/NDPK-A is a key tumor metastasis suppressor.
- Increased Nm23-H1 levels correlate with better cancer patient prognosis.
- Targeting Nm23-H1 is a promising strategy for anti-metastatic cancer therapies.
Purpose of the Study:
- To identify and characterize small molecules that enhance Nm23-H1 activity.
- To elucidate the mechanism of action for NMac1, a novel Nm23-H1 activator.
- To evaluate the anti-metastatic potential of NMac1 in preclinical models.
Main Methods:
- Small molecule screening and synthesis of NMac1 derivatives.
- Hydrogen/deuterium mass spectrometry (HDX-MS) for pharmacophore identification.
- In vitro cell-based assays (morphology, invasion, migration) and in vivo metastasis mouse model.
Main Results:
- NMac1 directly binds to Nm23-H1, increasing its NDPK activity via allosteric conformational changes.
- NMac1 treatment altered cancer cell morphology and actin cytoskeleton, inhibiting Rac1 activation.
- NMac1 suppressed breast cancer cell invasion and migration in vitro and metastasis in vivo.
Conclusions:
- NMac1 is a potent activator of Nm23-H1 with demonstrated anti-metastatic properties.
- The findings support NMac1's potential as a therapeutic agent for metastatic cancers.
- Understanding NMac1's mechanism provides insights into Nm23-H1 function in metastasis.
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Negative Regulator Molecules
Molecules and Compounds
Activation Energy
Positive Regulator Molecules

